Yau T, Galle PR, Decaens T, Sangro B, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet 2025 May 7:S0140-6736(25)00403-9. doi: 10.1016/S0140-6736(25)00403.
PMID: 40349714